US Stock MarketDetailed Quotes
NBY NovaBay Pharmaceuticals
- 0.6070
- -0.0080-1.30%
Close Oct 15 16:00 ET
- 0.6051
- -0.0019-0.31%
Post 19:03 ET
2.97MMarket Cap-9P/E (TTM)
0.6432High0.6050Low98.15KVolume0.6050Open0.6150Pre Close59.93KTurnover2.01%Turnover RatioLossP/E (Static)4.89MShares12.929052wk High-4.74P/B2.96MFloat Cap0.361152wk Low--Dividend TTM4.88MShs Float130156.1979Historical High--Div YieldTTM6.21%Amplitude0.3610Historical Low0.6100Avg Price1Lot Size
NovaBay Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -32.09%2.4M | 12.48%2.63M | 2.24%14.73M | 2.31%3.73M | -14.66%3.27M | -3.50%3.53M | -28.54%2.34M | 41.16%14.4M | 14.81%3.64M | 68.92%3.83M |
| Operating revenue | -32.25%2.39M | 12.52%2.62M | 2.18%14.69M | 2.34%3.72M | -14.70%3.26M | -3.74%3.52M | -28.62%2.33M | 41.20%14.37M | 14.61%3.63M | 68.92%3.82M |
| Cost of revenue | -54.99%808K | 13.26%837K | 3.14%6.83M | 1.27%1.91M | -1.65%1.43M | -1.59%1.8M | -49.35%739K | 79.53%6.62M | 26.29%1.89M | 103.79%1.45M |
| Gross profit | -8.45%1.59M | 12.13%1.79M | 1.47%7.9M | 3.42%1.82M | -22.61%1.84M | -5.39%1.74M | -11.80%1.6M | 19.43%7.78M | 4.59%1.76M | 52.93%2.38M |
| Operating expense | -5.20%2.65M | 14.26%3.37M | -16.58%12.9M | -41.20%2.61M | 4.31%2.95M | -30.08%2.79M | -29.81%2.95M | 0.55%15.46M | -8.78%4.44M | -26.29%2.83M |
| Selling and administrative expenses | -4.77%2.64M | 14.00%3.35M | -16.07%12.83M | -40.41%2.61M | 5.45%2.94M | -29.92%2.77M | -29.58%2.94M | -0.30%15.29M | -9.99%4.38M | -27.17%2.79M |
| -Selling and marketing expense | -13.28%1.02M | -14.64%1.06M | -16.65%6.5M | -27.04%1.41M | -6.54%1.72M | -42.40%1.18M | -37.35%1.24M | -3.65%7.8M | -9.90%1.94M | -10.97%1.84M |
| -General and administrative expense | 1.51%1.62M | 34.84%2.29M | -15.48%6.33M | -51.02%1.2M | 28.45%1.23M | -16.60%1.59M | -22.60%1.7M | 3.44%7.49M | -10.06%2.44M | -46.02%956K |
| Research and development costs | -59.09%9K | 90.00%19K | -60.92%68K | -93.94%4K | -73.17%11K | -45.00%22K | -64.29%10K | 295.45%174K | 725.00%66K | 310.00%41K |
| Operating profit | -0.19%-1.05M | -16.80%-1.57M | 34.86%-5M | 70.32%-798K | -144.20%-1.12M | 51.16%-1.05M | 43.53%-1.35M | 13.34%-7.68M | 15.81%-2.69M | 80.03%-457K |
| Net non-operating interest income expense | 40.12%-300K | -433K | -501K | 0 | ||||||
| Non-operating interest expense | -40.12%300K | --433K | ---- | ---- | ---- | --501K | --0 | ---- | ---- | ---- |
| Other net income (expense) | -31.82%-232K | -1.09M | -58.37%-4.64M | 40.00%-3.31M | -299.69%-641K | -5,766.67%-176K | -196.38%-2.93M | -281.72%-5.52M | 321K | |
| Gain on sale of security | -163.67%-163K | --259K | -99.43%20K | -94.98%49K | ---- | --256K | ---- | -23.64%3.52M | --976K | --492K |
| Special income (charges) | --0 | ---865K | 58.01%-2.59M | 59.45%-2.59M | --0 | --0 | --0 | ---6.18M | ---6.4M | --0 |
| -Less：Restructuring and merger&acquisition | ---- | ---- | --0 | --0 | --0 | ---- | ---- | ---561K | ---342K | --0 |
| -Less:Impairment of capital assets | ---- | ---- | -61.51%2.59M | ---- | ---- | ---- | ---- | --6.74M | ---- | ---- |
| -Gain on sale of business | --0 | ---865K | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Other non- operating income (expenses) | 84.03%-69K | ---480K | -647.83%-2.06M | -681.63%-766K | -274.85%-641K | -14,300.00%-432K | ---- | 82.50%-276K | 93.79%-98K | ---171K |
| Income before tax | 8.28%-1.59M | -129.74%-3.09M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 19.81%-1.73M | -1,111.71%-1.35M | -82.14%-10.61M | -5,093.67%-8.21M | 94.06%-136K |
| Income tax | ||||||||||
| Net income | 22.15%-1.59M | -84.82%-3.21M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,466.67%-1.74M | -82.14%-10.61M | -5,093.67%-8.21M | 94.06%-136K |
| Net income continuous Operations | 8.28%-1.59M | -129.74%-3.09M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 19.81%-1.73M | -1,111.71%-1.35M | -82.14%-10.61M | -5,093.67%-8.21M | 94.06%-136K |
| Net income discontinuous operations | --0 | 68.53%-124K | ---- | ---- | ---- | ---308K | ---394K | ---- | ---- | ---- |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 22.15%-1.59M | -84.82%-3.21M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,466.67%-1.74M | -82.14%-10.61M | -5,093.67%-8.21M | 94.06%-136K |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 0 | 380K | 24.75%7.06M | 5.06M | 0 | 2M | 0 | 5.66M | 0 | 5.66M |
| Net income attributable to common stockholders | 60.69%-1.59M | -106.67%-3.59M | -2.66%-16.7M | -11.74%-9.17M | 69.67%-1.76M | -87.10%-4.03M | -1,466.67%-1.74M | -147.98%-16.27M | -818.92%-8.21M | -153.08%-5.79M |
| Basic earnings per share | 96.92%-1.37 | 82.35%-5.25 | 60.79%-138.6 | 82.92%-28.5762 | 89.75%-12.95 | 11.23%-44.43 | -962.50%-29.75 | -92.02%-353.5 | -573.24%-167.3 | -106.29%-126.35 |
| Diluted earnings per share | 96.92%-1.37 | 82.35%-5.25 | 60.79%-138.6 | 82.92%-28.5762 | 89.75%-12.95 | 11.23%-44.43 | -962.50%-29.75 | -92.02%-353.5 | -573.24%-167.3 | -106.29%-126.35 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data